Research Topics
Species | Steven G DuBoisSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
131I-Metaiodobenzylguanidine therapy in children with advanced neuroblastomaS G Dubois
Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
Q J Nucl Med Mol Imaging 57:53-65. 2013..Given the documented activity of 131I-MIBG, future studies will need to evaluate the impact of radiation sensitizers on this activity and define the role of this agent in treating patients with newly diagnosed high-risk neuroblastoma...
Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trialSteven G DuBois
Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
Clin Cancer Res 18:2679-86. 2012..Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG together with fixed doses of vincristine and irinotecan...
Evaluation of polymorphisms in EWSR1 and risk of Ewing sarcoma: a report from the Childhood Cancer Survivor StudySteven G DuBois
Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143 0106, USA
Pediatr Blood Cancer 59:52-6. 2012..Ewing sarcoma is a malignant bone tumor characterized by a high frequency of somatic EWSR1 translocations. Ewing sarcoma is less common in people of African or African-American ancestry, suggesting a genetic etiology...- Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group studySteven G DuBois
Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
Cancer Chemother Pharmacol 69:1021-7. 2012..A pediatric phase I study of sunitinib capsules identified the maximum tolerated dose as 15 mg/m(2)/day. This study was conducted to evaluate sunitinib given as a powder formulation... - Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group studySteven G DuBois
Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
Clin Cancer Res 17:5113-22. 2011..The purpose of this study was to determine the recommended phase 2 dose, pharmacokinetics, pharmacodynamic effects, and preliminary antitumor activity of sunitinib in a pediatric population... - Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcomaSteven G DuBois
Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
Pediatr Blood Cancer 58:181-4. 2012..Circulating endothelial cells (CECs) have been detected at increased numbers in patients with solid cancers. CECs have not been systematically evaluated in patients with osteosarcoma... - Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical dataSteven G DuBois
Department of Pediatrics, University of California at San Francisco School of Medicine, San Francisco, California 94143 0106, USA
Cancer 116:749-57. 2010..For the current review, the authors summarized the available data supporting this approach... - Flow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrowSteven G DuBois
Department of Pediatrics, University of California San Francisco School of Medicine, San Francisco, CA 94143 0106, USA
Pediatr Blood Cancer 54:13-8. 2010..A new method for detecting circulating Ewing sarcoma cells using flow cytometry is described. This strategy exploits the nearly universal expression of CD99 and the lack of expression of CD45 by Ewing sarcoma cells... - Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: a report from the Children's Oncology GroupSteven G DuBois
Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143 0106, USA
Pediatr Blood Cancer 52:324-7. 2009..The purpose of this phase II clinical trial was to estimate the response rate of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma... - Late recurrence of ewing sarcoma during pregnancy: a report of 2 casesSteven G DuBois
Department of Pediatrics, University of California, San Francisco, CA 94143 0106, USA
J Pediatr Hematol Oncol 30:716-8. 2008..These receptors were not detected by immunohistochemistry. Increased medical surveillance during pregnancy may have resulted in ascertainment of recurrence in these 2 patients... - Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) projectSteven G DuBois
Department of Pediatrics, University of California, San Francisco, California, USA
Pediatr Blood Cancer 51:589-92. 2008..We aimed to describe the incidence, clinical characteristics, and outcome of patients with lung metastasis at initial diagnosis using a large international database... - Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trialKatherine K Matthay
Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, USA
J Nucl Med 53:1155-63. 2012..Our aim was to establish the maximum tolerated dose of no-carrier-added (NCA) (131)I-MIBG, with secondary aims of assessing tumor and organ dosimetry and overall response... - Predictors of acute chemotherapy-associated toxicity in patients with Ewing sarcomaJeremy M Sharib
Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143 0106, USA
Pediatr Blood Cancer 59:611-6. 2012..Patients with ES are treated with intensive chemotherapy regimens. We describe predictors of acute chemotherapy-associated toxicity in this population... - Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of ageDenah R Taggart
UCSF School of Medicine and Benioff Children s Hospital, San Francisco, CA 94143 0106, USA
J Clin Oncol 29:4358-64. 2011..Our aim was to determine which prognostic features could be used for optimal risk classification among patients younger than 18 months with metastatic disease... - Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanismsSabine Mueller
Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0106, USA
Cancer Lett 306:223-9. 2011..DNA repair enzyme Ku-86 was reduced in several neuroblastoma cells treated with vorinostat. Thus, vorinostat potentiates anti-neoplastic effects of radiation in neuroblastoma possibly due to down-regulation of DNA repair enzyme Ku-86... - 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastomaSarah French
Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143, USA
Pediatr Blood Cancer 60:879-84. 2013..The purpose of our report was to evaluate safety and response with MIBG therapy followed by myeloablative busulfan and melphalan (BuMel) with ASCT in patients with refractory neuroblastoma... - Racial differences in the incidence of mesenchymal tumors associated with EWSR1 translocationJennifer Worch
Department of Pediatrics, University of California, San Francisco, School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
Cancer Epidemiol Biomarkers Prev 20:449-53. 2011..The incidence of Ewing sarcoma varies by race, with very low rates among persons of African and East Asian ancestry. The incidence by race of other mesenchymal tumors that also harbor EWSR1 translocations has not been studied... - Clinical features and outcomes in patients with Ewing sarcoma and regional lymph node involvementMark A Applebaum
Department of Pediatrics, School of Medicine, University of California, San Francisco, California 94143 0106, USA
Pediatr Blood Cancer 59:617-20. 2012..A minority of patients with Ewing sarcoma present with regional lymph node involvement. We investigated if patient characteristics and outcomes differ between patients with Ewing sarcoma with and without regional node involvement... - Osteosarcoma in children 5 years of age or younger at initial diagnosisJennifer Worch
Department of Pediatrics and Department of Epidemiology Biostatistics, University of California, San Francisco School of Medicine, San Francisco, California, USA
Pediatr Blood Cancer 55:285-9. 2010..Since osteosarcoma is extremely rare in children < or =5 years of age, we sought to investigate if tumor characteristics, treatment strategies, and outcomes differ compared to older patients... - Response, survival, and toxicity after iodine-131-metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adultsAlexei L Polishchuk
Department of Pediatrics, University of California at San Francisco School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California, USA
Cancer 117:4286-93. 2011..The objective of the current study was to characterize the toxicity and activity of this therapy in older patients... - Clinical features and outcomes in patients with extraskeletal Ewing sarcomaMark A Applebaum
Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California, USA
Cancer 117:3027-32. 2011..The purpose of this study was to investigate whether patient characteristics, treatment strategies, and outcomes differ between skeletal Ewing sarcoma and extraskeletal Ewing sarcoma (EES)... - Clinical features and outcomes in patients with secondary Ewing sarcomaMark A Applebaum
Department of Pediatrics, University of California, San Francisco School of Medicine, San Francisco, California 94143 0106, USA
Pediatr Blood Cancer 60:611-5. 2013..Ewing sarcoma (EWS) is rarely diagnosed as a second malignancy. We sought to describe a cohort of patients with secondary EWS and investigate if patient characteristics and survival differ between patients with secondary and primary EWS... - Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastomaSteven G DuBois
Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA
J Clin Oncol 22:2452-60. 2004..Bone marrow tumor at time of treatment was the most useful predictor of hematotoxicity, whereas whole-body radiation dose was the most useful predictor of failure to recover platelets after AHSCT... - Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastomaSteven G DuBois
Department of Pediatrics, UCSF School of Medicine, Box 0106, San Francisco, CA 94143 0106, USA
Nucl Med Biol 35:S35-48. 2008..Neuroblastoma is the most common pediatric extracranial solid cancer. This tumor is characterized by metaiodobenzylguanidine (MIBG) avidity in 90% of cases, prompting the use of radiolabeled MIBG for targeted radiotherapy in these tumors... - Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcomaSteven G DuBois
University of California San Francisco UCSF School of Medicine, San Francisco, CA, USA
Nat Rev Clin Oncol 6:251-3. 2009..Subgroup analysis suggested that patients with large, localized tumors benefited from the addition of etoposide, whereas patients with metastases did not... - Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology GroupSteven G DuBois
Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M696, San Francisco, CA 94143 0106, USA
Int J Mol Imaging 2012:250834. 2012..0002). Conclusions. NET protein expression in neuroblastoma correlates with MIBG avidity. MYCN amplified tumors have lower NET protein expression... - Ethnic and racial differences in patients with Ewing sarcomaJennifer Worch
Department of Pediatrics, University of California at San Francisco School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, USA
Cancer 116:983-8. 2010..The goal of the current study was to evaluate racial and ethnic differences in presentation and overall survival (OS) among patients diagnosed with ES before age 40 years... - Development of anaplastic Wilms tumor and subsequent relapse in a child with diaphanospondylodysostosisSarah K Tasian
Department of Pediatrics, Division of Pediatric Hematology Oncology, University of California, San Francisco School of Medicine, San Francisco, CA, USA
J Pediatr Hematol Oncol 34:548-51. 2012..We describe a patient with DSD who developed bilateral hyperplastic nephroblastomatosis that ultimately evolved into therapy-resistant anaplastic Wilms tumor (nephroblastoma)... - Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systemsSwati S More
Departments of Bioengineering and Therapeutic Sciences, UCSF School of Medicine and UCSF Benioff Children s Hospital, San Francisco, California 94158, USA
Clin Cancer Res 17:2339-49. 2011.... - Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapySiavash Jabbari
Department of Radiation Oncology, University of California, San Francisco, CA, USA
Int J Radiat Oncol Biol Phys 75:177-82. 2009..To evaluate the role of radiation therapy (RT) as a component of multimodality therapy for pediatric desmoids... - Characteristics and outcomes of patients with Ewing sarcoma over 40 years of age at diagnosisErin E Karski
Department of Pediatrics, UCSF School of Medicine, 505 Parnassus Avenue, M646, San Francisco, CA 94143 0106, United States Electronic address
Cancer Epidemiol 37:29-33. 2013..Independent of differences in these characteristics, older patients also have a lower survival rate...